跳到正文
OurGMP·· 3 天前AI 评分68

OurGMP解读Dr. Reddy's印度Bachupally工厂FDA 483的7项观察项

印度Dr. Reddy's Laboratories FDA 483解析

AI 导读

Dr. Reddy's Laboratories Ltd.印度特伦甘纳邦Bachupally工厂在2026年6月16日至19日、6月22日至25日检查后收到FDA 483,6月25日签发的原文共6页、列7项观察项。

正文
微信视频号封面
微信视频号 · OurGMP

印度Dr. Reddy FDA 483 观察项解读
#FDA #483

在微信原文观看视频号

受检企业:Dr. Reddy's Laboratories Ltd.,印度特伦甘纳邦 Bachupally

检查日期:2026/6/16–6/19、6/22–6/25

签发日期:2026/6/25, 原文共 6 页、7 项观察项

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

在对贵公司进行检查期间,我们观察到:

OBSERVATION 1
观察项 1(原文第 1–3 页)

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate aseptic practices. During filling of drug product batch number (b)(4) on June 18, 2026, in the (b)(4) filling line, inadequate aseptic practices were observed. Specifically,

为防止声称无菌的药品发生微生物污染而制定的规程,未包含充分的无菌操作规范。2026 年6月18日,在 (b)(4) 灌装线灌装 (b)(4) 药品、批号 (b)(4) 期间,观察到无菌操作不规范。具体如下:

A. The (b)(4) and stopper bowl were assembled into the (b)(4) and were uncovered prior to initiation of the decontamination cycle. As a result, these sterilized components were exposed to the (b)(4) decontamination agent prior to filling operations, compromising the sterility of these items. Sterilized components introduced into the (b)(4) should not be subjected to conditions that could compromise their sterility assurance.

A. (b)(4) 与胶塞料斗在去污循环启动之前即已装入 (b)(4),且未加覆盖。因此,这些已灭菌部件在灌装操作开始前就暴露于 (b)(4) 去污剂中,其无菌性受到破坏。装入 (b)(4) 的已灭菌部件,不应处于可能损害其无菌保证的条件之下。

B. During loading of (b)(4) sterilized stoppers into the (b)(4), the (b)(4), which is not sterilized and is only exposed to the (b)(4) decontamination cycle, is positioned directly above the (b)(4). When (b)(4), the (b)(4) blocks unidirectional first air to the (b)(4), exposing the sterilized (b)(4) to potential microbial contamination.

B. 在将 (b)(4) 已灭菌胶塞装入 (b)(4) 的过程中,未经灭菌、仅经 (b)(4) 去污循环处理的 (b)(4) 被置于 (b)(4) 正上方。当 (b)(4) 时,该 (b)(4) 遮挡了吹向 (b)(4) 的单向流首过空气(first air),使已灭菌的 (b)(4) 面临潜在微生物污染风险。

C. During loading of the (b)(4) sterilized stoppers into the (b)(4), a large number of stoppers were observed making direct contact with an unsterilized (b)(4) positioned above the (b)(4). Contact between sterilized stoppers and an unsterilized surface compromise the sterility of the stoppers prior to their placement on vials.

C. 在将 (b)(4) 已灭菌胶塞装入 (b)(4) 时,观察到大量胶塞与位于 (b)(4) 上方、未经灭菌的 (b)(4) 直接接触。已灭菌胶塞与未灭菌表面接触,会在胶塞被放置到西林瓶上之前破坏胶塞的无菌性。

D. During installation of the (b)(4), each (b)(4) was assembled onto a non-sterile (b)(4). Although each (b)(4) was individually protected by a cover prior to installation, the top of each protective cover was observed contacting the unsterile (b)(4). Upon removal of the protective cover, the cover was slid along the full length of the (b)(4), such that the top portion of the cover contacted the entire length of the (b)(4), including the (b)(4). This practice compromises the sterility of the (b)(4) and presents a direct contamination risk to the drug product.

D. 在安装 (b)(4) 时,每个 (b)(4) 均被装配到未经灭菌的 (b)(4) 上。尽管每个(b)(4) 在安装前均有单独保护罩,但观察到每个保护罩的顶部与未灭菌的 (b)(4) 接触。取下保护罩时,保护罩沿 (b)(4) 全长滑动,使罩顶部接触到 (b)(4) 的整个长度,包括(b)(4)。该操作破坏 (b)(4) 的无菌性,并对药品构成直接污染风险。

E. The (b)(4), under which vials are capped during the stoppering operation, is positioned such that it blocks unidirectional first air to all vials passing beneath it. The (b)(4) is not sterilized and is only exposed to the (b)(4) decontamination cycle. Because all vials must pass under this (b)(4) during stoppering, this unsterilized surface is in direct proximity to open vials and exposed stoppers, representing an uncontrolled contamination risk to the drug product.

E. 加塞工序中,西林瓶在 (b)(4) 下方完成封盖;该 (b)(4) 的位置遮挡了所有从其下方经过的西林瓶的单向流首过空气。该 (b)(4) 未经灭菌,仅经过 (b)(4) 去污循环处理。由于所有西林瓶在加塞时都必须从该 (b)(4) 下方通过,这一未灭菌表面与敞口西林瓶及裸露胶塞直接邻近,对药品构成不受控的污染风险。

F. During filling of (b)(4) drug product batch number (b)(4) on June 22, 2026, in the (b)(4) Restricted Access Barrier System (RABS) vial filling line (Grade A within a Grade B environment), inadequate aseptic practices were observed. Specifically,

F. 2026 年 6 月 22 日,在 (b)(4) 限制进入屏障系统(RABS)西林瓶灌装线(B级背景下的 A 级区)灌装 (b)(4) 药品、批号 (b)(4) 期间,观察到无菌操作不规范。具体如下:

i. Operators were observed moving back and forth between the Grade B area and the Grade A air-supplied area outside the RABS through which stoppered vials transit via conveyor belt to the capping machine. Although a (b)(4) is present between the operators and the stoppered vials on the conveyor, operators were observed reaching (b)(4) into the Grade A zone to manually discard vials identified as lacking stoppers or as (b)(4). This practice introduces personnel, who have been present in the lower-classified Grade B environment, into direct proximity with potentially (b)(4) vials within the Grade A zone, compromising the sterility of the drug product. The repeated ingress and egress of operator arms (b)(4) (b)(4), as well as operators extending over the (b)(4), disrupts the integrity of the Grade A air supply and increases the risk of microbial contamination of the drug product. This inadequate aseptic practice is visible at minute 10:59:19 in airflow simulation video IMN09, titled "Removal of unstoppered or (b)(4) or fallen vials over (b)(4) (b)(4) conveyor (Smoke Study, (b)(4))", filmed on August 22, 2025.

i. 观察到操作人员在 B 级区与 RABS 外的 A 级送风区之间来回走动;已加塞西林瓶经传送带穿过该 A 级区送往轧盖机。尽管操作人员与传送带上已加塞西林瓶之间设有 (b)(4),仍观察到操作人员将 (b)(4) 伸入 A 级区,手动剔除被判定为缺塞或 (b)(4)的西林瓶。该操作使曾处于较低洁净级别 B 级环境的人员,直接进入 A 级区内可能(b)(4) 的西林瓶近旁,损害药品的无菌性。操作人员手臂反复 (b)(4) 进出,以及操作人员身体探过 (b)(4),破坏了 A 级送风的完整性,并增加药品受微生物污染的风险。该不规范无菌操作见于 2025 年 8 月 22 日拍摄的气流模拟视频 IMN09 第 10 分 59 秒19帧处,视频标题为《在 (b)(4) 传送带上移除未加塞、(b)(4) 或倒伏西林瓶(烟雾试验,(b)(4))》。

OBSERVATION 2
观察项 2(原文第 3–4 页)

Aseptic processing environmental monitoring procedures are inadequate in the (b)(4) filling line. Specifically,

(b)(4) 灌装线的无菌工艺环境监测规程不充分。具体如下:

A. On June 24, 2026, following filling of drug product batch number (b)(4), environmental monitoring failed to include viable surface monitoring of the (b)(4) and stopper bowl. The inadequate (b)(4) design does not allow for effective monitoring strategies for these indirect product-contact surfaces, which compromises sterility assurance of the drug product as the potential microbial load on these components during filling operations remains unknown.

A. 2026 年 6 月 24 日,在灌装 (b)(4) 药品、批号 (b)(4) 之后,环境监测未包含对 (b)(4) 及胶塞料斗的活性微生物(viable)表面监测。(b)(4) 设计存在缺陷,无法对这些间接产品接触表面实施有效的监测策略;由于灌装期间这些部件上的潜在微生物负荷未知,药品的无菌保证因此受到损害。

B. On June 23, 2026, following filling of (b)(4) drug product batch number (b)(4) and (b)(4) drug product batch number (b)(4), improper (b)(4) fingertip contact plate monitoring technique was observed, as approximately only one second of non-rolling finger contact with the contact plates was observed. This inadequate contact time undermines the reliability of environmental monitoring data.

B. 2026 年 6 月 23 日,在灌装 (b)(4) 药品(批号 (b)(4))和 (b)(4) 药品(批号(b)(4))之后,观察到 (b)(4) 指尖接触碟(contact plate)监测操作不规范:手指与接触碟仅非滚动接触约 1 秒。接触时间不足,削弱了环境监测数据的可靠性。

C. On June 23, 2026, during environmental monitoring of the (b)(4) (b)(4) module of the (b)(4) following filling of (b)(4) drug product batch number (b)(4), complete absence of a non-viable particle monitor in the transfer conveyor area during (b)(4) unloading was observed. This constitutes a critical gap in the environmental monitoring program as adequate air quality control during a sterility-critical operation cannot be demonstrated.

C. 2026 年 6 月 23 日,在灌装 (b)(4) 药品、批号 (b)(4) 后,对 (b)(4) 的 (b)(4) 模块进行环境监测时,发现转运传送带区域在 (b)(4) 卸料期间完全未设置非活性粒子(non-viable particle)监测仪。这构成环境监测计划的一项重大缺口,因为无法证明在这一对无菌性至关重要的操作期间空气质量得到了充分控制。

OBSERVATION 3
观察项 3(原文第 4 页)

The (b)(4) drug substance manufacturing process lacks adequate controls to prevent microbial contamination of in-process intermediates. Specifically,

(b)(4) 原料药生产工艺缺乏充分控制,无法防止工艺中间体受到微生物污染。具体如下:

A (b)(4) microorganism was identified in the (b)(4) (batch number (b)(4)), indicating contamination events across multiple unit operations.

在 (b)(4)(批号 (b)(4))中检出 (b)(4) 微生物,表明污染事件涉及多个单元操作。

OBSERVATION 4
观察项 4(原文第 4–5 页)

Aseptic practices observed in air visualization studies for (b)(4) drug product filling operations are inadequate in that first air was obstructed in different (b)(4) critical zones during aseptic processing interventions. Specifically,

在针对 (b)(4) 药品灌装操作的气流可视化(烟雾)研究中观察到的无菌操作不充分:无菌工艺干预期间,多个 (b)(4) 关键区域的单向流首过空气受到遮挡。具体如下:

1. Airflow visualization (smoke) studies conducted on 17/12/2024 (December 17, 2024) for Intervention: Filling machines (b)(4) adjustment vial maximum load (b)(4) at (b)(4), show that a (b)(4) positioned above the (b)(4) would likely block first air to all vials as they are transported in the (b)(4).

1. 2024 年 12 月 17 日(17/12/2024)针对“干预:灌装机 (b)(4) 调整、西林瓶最大装载 (b)(4)(位于 (b)(4))”开展的气流可视化(烟雾)研究显示,置于 (b)(4) 上方的(b)(4) 很可能在西林瓶经 (b)(4) 输送时遮挡所有西林瓶的首过空气。

2. Airflow visualization (smoke) studies conducted on 19/12/2024 (December 19, 2024, 19:22:22) for Intervention: Adjustment of stoppering machine parts (b)(4), show that a (b)(4) positioned above the (b)(4) and a (b)(4) hand blocked first air to exposed stoppers.

2. 2024 年 12 月 19 日(19/12/2024,19:22:22)针对“干预:调整加塞机部件(b)(4)”开展的气流可视化(烟雾)研究显示,置于 (b)(4) 上方的 (b)(4) 以及 (b)(4) 手遮挡了吹向裸露胶塞的首过空气。

The (b)(4) and/or (b)(4) hand were positioned such that they blocked first air to either open vials or exposed stoppers (direct product-contact surfaces) in Grade A critical zones within the (b)(4) during inherent and non-inherent interventions, increasing the risk of microbiological contamination of the sterile drug product.

在固有干预与非固有干预期间,(b)(4) 和/或 (b)(4) 手所处的位置,遮挡了 (b)(4)内 A 级关键区中敞口西林瓶或裸露胶塞(直接接触产品的表面)的首过空气,增加了无菌药品受微生物污染的风险。

OBSERVATION 5
观察项 5(原文第 5 页)

The visual inspection program for (b)(4) drug product is inadequate. Specifically,

(b)(4) 药品的目视检查(灯检)程序不充分。具体如下:

A. The classification of defect categories (i.e., critical, major, and minor) is not adequately justified. For example, black and colored particles, which present a significant risk to patient safety and are indicative of potential contamination, have been inappropriately classified as major defects rather than critical defects.

A. 缺陷类别(即关键、主要、次要)的划分缺乏充分依据。例如,黑色及有色微粒对患者安全构成重大风险,并提示可能存在污染,却被不恰当地归为主要缺陷,而非关键缺陷。

B. Visual inspection qualification kits include vials marked with numbers visible to personnel performing qualification testing. This practice compromises the integrity of the qualification process, as inspectors may become familiar with the identity and location of defective vials prior to qualification testing.

B. 目视检查资质确认套件中包含标有编号、且编号对执行资质确认测试的人员可见的西林瓶。该做法损害资质确认过程的完整性,因为检查人员可能在测试前就已熟悉缺陷瓶的标识及其位置。

OBSERVATION 6
观察项 6(原文第 5–6 页)

Your firm failed to review in-process bioburden testing results for (b)(4) drug substance, as microbial colony growth was detected in multiple in-process (b)(4) samples. The microorganism recoveries were not identified, and root cause investigations were not performed. Specifically,

贵公司未对 (b)(4) 原料药的过程生物负载(bioburden)检测结果进行审核:多个过程 (b)(4) 样品中检出微生物菌落生长,但未对检出的微生物进行鉴定,也未开展根本原因调查。具体如下:

A. Batch No. (b)(4): Bioburden testing conducted on April 25, 2025, yielded (b)(4) microbial colonies.

A. (b)(4),批号 (b)(4):2025 年 4 月 25 日进行的生物负载检测检出 (b)(4) 个微生物菌落。

B. Batch No. (b)(4): Bioburden testing conducted on May 2, 2025, yielded (b)(4) microbial colony.

B. (b)(4),批号 (b)(4):2025 年 5 月 2 日进行的生物负载检测检出 (b)(4) 个微生物菌落。

C. Batch No. (b)(4): Bioburden testing conducted on May 10, 2025, yielded (b)(4) microbial colonies.

C. (b)(4),批号 (b)(4):2025 年 5 月 10 日进行的生物负载检测检出 (b)(4) 个微生物菌落。

OBSERVATION 7
观察项 7(原文第 6 页)

Your firm failed to ensure that operators working in aseptic manufacturing areas are adequately trained, as evidenced by deficient On-the-Job Training (OJT) records for personnel in the (b)(4) area. Specifically,

贵公司未能确保在无菌生产区域工作的操作人员经过充分培训,(b)(4) 区域人员的岗位培训(On-the-Job Training,OJT)记录存在缺陷即为明证。具体如下:

Review of the On-the-Job Training Record (record number (b)(4) for Employee ID: (b)(6)) shows that individual skill training sessions for critical aseptic manufacturing operations were documented as lasting as few as 29 minutes (Participate in BPR execution and closure activity, documented November 10, 2025, (b)(4)) and 9 minutes (Procedure for operation and cleaning of (b)(4) LAF, documented November 10, 2025, (b)(4)).

查阅岗位培训记录(记录编号 (b)(4),员工编号 (b)(6))发现,针对关键无菌生产操作的单项技能培训,记录时长最短仅 29 分钟(“参与批生产记录(BPR)的执行与关闭活动”,记录日期 2025 年 11 月 10 日,(b)(4))和 9 分钟(“(b)(4) 层流设备(LAF)的操作与清洁规程”,记录日期 2025 年 11 月 10 日,(b)(4))。

These session durations do not provide reasonable assurance that the employee received sufficient training to competently perform complex aseptic operations, including equipment cleaning and sterilization activities that are critical to product sterility assurance.

上述培训时长无法合理保证该员工已接受足够培训,能够胜任复杂无菌操作,包括设备清洁与灭菌等对产品无菌保证至关重要的活动。

来听一听看一看近期公布国内企业的FDA 483吧!

近期FDA发布的MNC的FDA 483汇总

微信视频号封面
微信视频号 · OurGMP

诺华制药施泰因FDA483 观察项解读

在微信原文观看视频号

微信视频号封面
微信视频号 · OurGMP

浙江天宇药业FDA 483 观察项解读
#FDA #483

在微信原文观看视频号

来源:OurGMP · mp.weixin.qq.com